Sanofi and CD&R have signed a share purchase agreement for the sale of a 50% stake in the consumer health business.

Subject to shareholder approval at the subsequent Annual General Meeting (AGM), the Board of Directors of Sanofi Consumer ...

Sanofi is closer to selling a 50% controlling stake in the consumer health business, Opella to private equity Clayton ...

The medicine is so popular that most paracetamol products ... the-counter vitamins, minerals, and supplements market. Given Opella’s significant economic contribution to France, Sanofi’s ...

A line extension of one of Sanofi Indias flagship brand Combiflam, the launch of this new product marks the companys foray into the OTC headache segment in India.On 11 November 2014, Sanofi India ...

These products are sold principally in the prescription market, but the company also develops over-the-counter medication as well. Sanofi now covers seven major therapeutic areas: Sanofi’s CEO ...

Zantac was originated by GSK and launched by the company in the early 1980s, which sold it as a prescription and over-the-counter (OTC) product for indications like heartburn and acid indigestion ...

If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025Priority ...

About Altimmune Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a ...

If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025 Priority Review granted based on positive pivotal results demonstrat ...